Equities researchers at Goldman Sachs Group started coverage on shares of Humana (NYSE:HUM) in a research report issued on Wednesday. The brokerage set a “buy” rating and a $305.00 price target on the insurance provider’s stock. Goldman Sachs Group’s price objective would suggest a potential upside of 18.05% from the company’s previous close.
Other analysts have also recently issued reports about the company. Credit Suisse Group began coverage on Humana in a research report on Thursday, November 2nd. They issued a “neutral” rating and a $256.00 price target on the stock. Zacks Investment Research cut Humana from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 17th. ValuEngine cut Humana from a “buy” rating to a “hold” rating in a research report on Tuesday, December 19th. Morgan Stanley lowered their price target on Humana from $276.00 to $270.00 and set an “overweight” rating on the stock in a research report on Thursday, November 9th. Finally, Cowen reiterated a “buy” rating and issued a $285.00 price target on shares of Humana in a research report on Wednesday, December 13th. Twelve analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Humana has a consensus rating of “Buy” and an average price target of $258.62.
Humana (NYSE HUM) traded up $7.08 on Wednesday, hitting $258.36. The stock had a trading volume of 1,346,100 shares, compared to its average volume of 1,125,867. Humana has a 1-year low of $186.25 and a 1-year high of $264.56. The company has a market capitalization of $37,620.00, a PE ratio of 20.34, a PEG ratio of 1.66 and a beta of 0.88. The company has a current ratio of 1.61, a quick ratio of 1.61 and a debt-to-equity ratio of 0.35.
Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share for the quarter, beating analysts’ consensus estimates of $3.27 by $0.12. Humana had a return on equity of 15.99% and a net margin of 3.49%. The firm had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $13.41 billion. During the same period in the prior year, the business posted $3.18 earnings per share. The business’s revenue was down 3.0% compared to the same quarter last year. analysts anticipate that Humana will post 11.63 earnings per share for the current year.
Humana announced that its Board of Directors has approved a stock repurchase program on Thursday, December 14th that allows the company to buyback $3.00 billion in outstanding shares. This buyback authorization allows the insurance provider to buy shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its shares are undervalued.
In other news, SVP Jody L. Bilney sold 7,054 shares of the company’s stock in a transaction on Monday, December 18th. The stock was sold at an average price of $247.89, for a total transaction of $1,748,616.06. Following the transaction, the senior vice president now owns 11,704 shares of the company’s stock, valued at $2,901,304.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Timothy S. Huval sold 1,382 shares of the company’s stock in a transaction on Tuesday, December 19th. The shares were sold at an average price of $246.04, for a total value of $340,027.28. Following the transaction, the vice president now directly owns 11,557 shares in the company, valued at approximately $2,843,484.28. The disclosure for this sale can be found here. Insiders have sold 10,115 shares of company stock worth $2,501,627 in the last 90 days. Company insiders own 0.80% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of HUM. Neuberger Berman Group LLC lifted its stake in shares of Humana by 674.5% during the second quarter. Neuberger Berman Group LLC now owns 24,047 shares of the insurance provider’s stock valued at $5,786,000 after acquiring an additional 20,942 shares during the period. Cambridge Investment Research Advisors Inc. lifted its stake in shares of Humana by 4.6% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 2,095 shares of the insurance provider’s stock valued at $504,000 after acquiring an additional 92 shares during the period. Meiji Yasuda Life Insurance Co acquired a new position in shares of Humana during the second quarter valued at $361,000. Atlantic Trust Group LLC lifted its stake in shares of Humana by 4.9% during the second quarter. Atlantic Trust Group LLC now owns 53,603 shares of the insurance provider’s stock valued at $12,898,000 after acquiring an additional 2,486 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. lifted its stake in shares of Humana by 228.4% during the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 3,691 shares of the insurance provider’s stock valued at $888,000 after acquiring an additional 2,567 shares during the period. 94.01% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This story was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://transcriptdaily.com/2018/01/05/humana-hum-coverage-initiated-at-goldman-sachs-group.html.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.